Chronic Liver Disease

Latest News

Renaming and Redefining Pediatric Nonalcoholic Fatty Liver Disease

By

Jennifer Champagne, PharmD, RPh, BCPS

An international panel proposed updated criteria for disease diagnosis, along with a more age-appropriate disease name and definition, for pediatric patients with NAFLD.

Debunking the “6-Month Rule” for Liver Transplantation: Relapse Prevention in Alcohol-Related Cirrhosis

By

Rita Aghjayan

For patients with alcohol-related liver disease who require transplantation, there is mixed evidence supporting the requirement that patients abstain from alcohol consumption for 6 months prior to transplantation.

Efficacy of Long-Acting Cabotegravir Plus Rilpivirine in Patients With HIV Coinfected With Asymptomatic Hepatitis C

By

Sweta Gupta

Researchers sought to determine the safety and efficacy of treatment with long-acting cabotegravir plus rilpivirine in patients with HIV coinfected with asymptomatic hepatitis c virus.

Red Meat Intake Associated With Nonalcoholic Fatty Liver Disease

By

Vincent Soreca

Investigators assessed the association between meat intake and risk for nonalcoholic fatty liver disease in a study cohort with low overall consumption of red meat.

Passive Smoking in Childhood Associated With Increased Risk for Adult Fatty Liver

By

Virginia A. Schad, PharmD, RPh

Investigators assessed the relationship between passive smoking in children and adults with adult risk for fatty liver.

Projected Long-Term Impact of the COVID-19 Pandemic on Outcomes Associated With Hepatitis C Virus

By

Sweta Gupta

Researchers conducted a modeling study to determine the projected long-term impact of the COVID-19 pandemic on outcomes associated with hepatitis C virus care.

Medication Treatments Lacking For Active Opioid Use Disorder in Veterans With Cirrhosis

By

Rita Aghjayan

Investigators assessed the factors associated with medication treatment for opioid use disorder and whether it is linked to hepatic decompensation or death in patients with cirrhosis and active opioid use disorder.

Outcomes of Rapid Treatment With Sofosbuvir-Velpatasvir in Patients With Hepatitis C Virus who use Injectable Drugs

By

Madison Heck, MPH, CHES

Researchers conducted a study that compared rapid treatment with a 7-day course of sofosbuvir-velpatasvir with usual compare in patients with hepatitis C virus infection who use injectable drugs.

Livmarli Approved for Cholestatic Pruritus in Alagille Syndrome

By

Brian Park, PharmD

The approval was based on data from the phase 2b ICONIC study, along with 5 years of data from supportive studies.

Infigratinib Shows Meaningful Clinical Activity for Chemotherapy-Refractory Cholangiocarcinoma With FGFR2 Fusions or Rearrangements

By

Colby Stong

Investigators evaluated the antitumor activity of infigratinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma and FGFR2 alterations.

Model Evaluates HCV Elimination Forecast Among People Who Inject Drugs

By

Rita Aghjayan

Based on a mathematical model, investigators evaluated improvements to the care cascade for people with hepatitis C virus who inject drugs.

Insights on Improving Care for Patients With NAFLD/NASH

By

Vincent Soreca

The American Gastroenterological Association offered strategies for clinical practice, future research, and policy agenda for the treatment of patients with NAFLD and NASH.

Overall Cancer Incidence, Mortality Lower for US Hispanics

The researchers note that among Hispanic individuals in the continental United States and Hawaii in 2021, an estimated 176,600 new cancer cases and 46,500 cancer deaths will occur.

Broad Down-Staging Is Feasible Per Current UNOS-DS Guidelines for Hepatocellular Carcinoma

By

Colby Stong

The investigators sought to determine the down-staging success rate and intention-to-treat outcomes according to uniform criteria in patients with hepatocellular carcinoma.

Liver Transplantation Candidates With COVID-19 Have High Risk for Early Death

By

Colby Stong

Researchers investigated the impact of COVID-19 on patients waiting for liver transplants, as well as on the clinical course following transplantation.

Dose-Dependent Fatty Acid Synthase Inhibitor Reduces Liver Fat in Nonalcoholic Steatohepatitis

By

Rita Aghjayan

Researchers aimed to assess the safety and efficacy of fatty acid synthase inhibitor TVB-2640 on liver fat and biomarkers for liver and metabolic health in patients with NASH.

Urban-Rural Disparity Seen in New Liver Cancer Cases

There has been a widening rural-urban disparity in changes in new cases of hepatocellular carcinoma (HCC) during the past two decades.

Gestational Hypercholanemia Linked to Low Birth Weight, Intrauterine Growth Restriction

By

Rita Aghjayan

Investigators aimed to determine the association between maternal gestational elevated serum total bile acid concentrations and the risk for intrauterine growth restrictions.

Long-Acting Octreotide Therapy Gets Orphan Drug Status for Polycystic Liver Disease

By

Brian Park, PharmD

CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot.

Sleep-Wake Disturbance Highly Prevalent in Populations With Liver Disease

By

Vincent Soreca

Researchers summarized the reciprocal interaction between sleep and liver diseases, including cirrhosis, and investigated potential approaches for therapeutic interventions.